Insys Therapeutics Stock Price, News & Analysis (NASDAQ:INSY) Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insys Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$0.23MA: $23,687,640.18▼$65,799,000.0052-Week Range N/AVolumeN/AAverage Volume9.52 million shsMarket Capitalization$21.71 millionP/E RatioN/ADividend YieldN/ABeta3.21 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CUSIPN/A CIK1516479 Webhttp://www.insysrx.com/ Phone480-500-3127Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$82.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($1.39) Net Income$-124,510,000.00 Net Margins-346.61% Return on Equity-1,430.37% Return on Assets-64.04%Miscellaneous Employees226 Outstanding Shares74,570,000Market Cap$21.71 million Next Earnings Date11/4/2019 (Estimated) OptionableOptionable Receive INSY News and Ratings via Email Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter. Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions What is Insys Therapeutics' stock symbol? Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY." When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work? Insys Therapeutics shares split on the morning of Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split. How were Insys Therapeutics' earnings last quarter? Insys Therapeutics Inc (NASDAQ:INSY) issued its earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company had revenue of $7.63 million for the quarter, compared to analysts' expectations of $14.95 million. Insys Therapeutics had a negative return on equity of 1,430.37% and a negative net margin of 346.61%. Insys Therapeutics's quarterly revenue was down 68.1% compared to the same quarter last year. During the same period last year, the business earned ($0.19) EPS. View Insys Therapeutics' Earnings History. When is Insys Therapeutics' next earnings date? Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Insys Therapeutics. What price target have analysts set for INSY? 4 Wall Street analysts have issued 1-year price targets for Insys Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they expect Insys Therapeutics' stock price to reach $6.60 in the next year. View Analyst Price Targets for Insys Therapeutics. What is the consensus analysts' recommendation for Insys Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insys Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insys Therapeutics. Has Insys Therapeutics been receiving favorable news coverage? News stories about INSY stock have trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insys Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Insys Therapeutics. Who are some of Insys Therapeutics' key competitors? Some companies that are related to Insys Therapeutics include Aduro BioTech (ADRO), Trevena (TRVN), BioXcel Therapeutics (BTAI), NeuBase Therapeutics (NBSE), Galmed Pharmaceuticals (GLMD), Verastem (VSTM), Aquestive Therapeutics (AQST), Vaccinex (VCNX), Humanigen (HGEN), Cumberland Pharmaceuticals (CPIX), Mersana Therapeutics (MRSN), Neoleukin Therapeutics (NLTX), vTv Therapeutics (VTVT), Lipocine (LPCN) and Entasis Therapeutics (ETTX). What other stocks do shareholders of Insys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insys Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Medivation (MDVN) and NVIDIA (NVDA). Who are Insys Therapeutics' key executives? Insys Therapeutics' management team includes the folowing people: Mr. Steven J. Meyer, Exec. Chairman (Age 62)Mr. Saeed Motahari, CEO, Pres & Director (Age 53)Mr. Andrew G. Long, Chief Financial OfficerDr. Danny L. Tuck, Sr. VP of Quality OperationsMr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47) How big of a company is Insys Therapeutics? Insys Therapeutics has a market capitalization of $0.00 and generates $82.08 million in revenue each year. The specialty pharmaceutical company earns $-124,510,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Insys Therapeutics employs 226 workers across the globe.View Additional Information About Insys Therapeutics. What is Insys Therapeutics' official website? The official website for Insys Therapeutics is http://www.insysrx.com/. How can I contact Insys Therapeutics? Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected] MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 431 (Thanks for Voting!)Underperform Votes: 348 (Thanks for Voting!)Total Votes: 779MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/21/2019 by MarketBeat.com StaffFeatured Article: What is insider trading?